Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.
作者信息
Bayley S, Dobbs R J, Robinson B F
出版信息
Br J Clin Pharmacol. 1982 Oct;14(4):509-12. doi: 10.1111/j.1365-2125.1982.tb02021.x.
Abstract
1 The effect of oral nifedipine has been examined in patients with hypertension in whom arterial pressure was not adequately controlled by the combination of a beta-adrenoceptor antagonist (or alpha-methyldopa) and a diuretic. 2 In 42 patients, nifedipine (10 mg capsules) was added to the existing therapy in a final dose of 20-60 mg daily. Six patients had to stop the drug on account of side-effects. In the 36 patients who continued treatment, arterial pressure fell by an average of 24/9 mmHg supine and 26/10 mmHg standing. 3 In 11 of these patients who subsequently completed a double-blind, cross-over, placebo controlled trial, nifedipine (30-60 mg daily) was found to reduce arterial pressure by an average of 19/11 mmHg supine and 21/12 mmHg standing. 4 In all 11 patients who were changed to a sustained release preparation of nifedipine, control of arterial pressure was at least as good as it had been when taking the capsules.
摘要
相似文献
1
Nifedipine in the treatment of hypertension: report of a double-blind controlled trial.
Br J Clin Pharmacol. 1982 Oct;14(4):509-12. doi: 10.1111/j.1365-2125.1982.tb02021.x.
2
Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension.
J Clin Hypertens. 1987 Dec;3(4):579-88.
3
Role of nifedipine in treatment of hypertension.
Br Med J (Clin Res Ed). 1983 Jul 23;287(6387):257-9. doi: 10.1136/bmj.287.6387.257.
4
Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.
Br J Clin Pharmacol. 1987 Nov;24(5):591-7. doi: 10.1111/j.1365-2125.1987.tb03217.x.
5
Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.
Drugs. 1988;35 Suppl 4:22-6. doi: 10.2165/00003495-198800354-00006.
6
[Cicletanine administered with other antihypertensive agents].
Arch Mal Coeur Vaiss. 1989 Nov;82 Spec No 4:109-12.
7
8
9
A double-blind, placebo-controlled, crossover trial to investigate the additive hypotensive effect of a diuretic (mefruside) to that produced by nifedipine.
J Cardiovasc Pharmacol. 1987;10 Suppl 10:S53-6.
10
Effects of treatment with nifedipine and metoprolol in essential hypertension.
Eur J Clin Pharmacol. 1982;21(5):389-90. doi: 10.1007/BF00542324.
引用本文的文献
1
Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.
Clin Pharmacokinet. 1994 Jun;26(6):472-85. doi: 10.2165/00003088-199426060-00005.
2
Acute treatment of hypertensive crisis with nifedipine.
Br J Clin Pharmacol. 1983 Dec;16(6):725-7. doi: 10.1111/j.1365-2125.1983.tb02250.x.
3
Role of nifedipine in treatment of hypertension.
Br Med J (Clin Res Ed). 1983 Jul 23;287(6387):257-9. doi: 10.1136/bmj.287.6387.257.
4
Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension.
Eur J Clin Pharmacol. 1983;25(5):571-5. doi: 10.1007/BF00542340.
5
Haemodynamic effects of intravenous felodipine in normotensive and hypertensive subjects.
Drugs. 1985;29 Suppl 2:144-53. doi: 10.2165/00003495-198500292-00025.
6
Comparison of nifedipine, prazosin and hydralazine added to treatment of hypertensive patients uncontrolled by thiazide diuretic plus beta-blocker.
Postgrad Med J. 1987 Feb;63(736):99-103. doi: 10.1136/pgmj.63.736.99.
7
Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.
Eur J Clin Pharmacol. 1986;30(6):723-5. doi: 10.1007/BF00608223.
8
The management of hypertension.
Br J Clin Pharmacol. 1986;21 Suppl 2(Suppl 2):129S-142S. doi: 10.1111/j.1365-2125.1986.tb02862.x.
9
Treatment of severe hypertension and hypertensive crises with nifedipine.
West J Med. 1987 Jun;146(6):701-4.
10
Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.
Cardiovasc Drugs Ther. 1988 Mar;1(6):625-56. doi: 10.1007/BF02125750.
本文引用的文献
1
Effects of nifedipine on resistance vessels, arteries and veins in man.
Br J Clin Pharmacol. 1980 Nov;10(5):433-8. doi: 10.1111/j.1365-2125.1980.tb01784.x.
2
Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension.
Circulation. 1980 May;61(5):913-9. doi: 10.1161/01.cir.61.5.913.
3
Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man.
Clin Sci (Lond). 1981 Dec;61 Suppl 7:65s-68s. doi: 10.1042/cs061065s.
4
Response of forearm resistance vessels to verapamil and sodium nitroprusside in normotensive and hypertensive men: evidence for a functional abnormality of vascular smooth muscle in primary hypertension.
Clin Sci (Lond). 1982 Jul;63(1):33-42. doi: 10.1042/cs0630033.
5
Relation of hydralazine plasma concentration to dosage and hypotensive action.
Clin Pharmacol Ther. 1972 May-Jun;13(3):420-5. doi: 10.1002/cpt1972133420.
6
[Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].
Arzneimittelforschung. 1972 Feb;22(2):334-44.
7
Nifedipine, a new antihypertensive with rapid action.
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):528-32. doi: 10.1002/cpt1977225part1528.
8
Production of ischaemic cardiac pain by nifedipine.
Br Med J. 1978 May 6;1(6121):1181-2. doi: 10.1136/bmj.1.6121.1181.
9
Treatment of hypertension with nifedipine, a calcium antagonistic agent.
Circulation. 1979 May;59(5):1056-62. doi: 10.1161/01.cir.59.5.1056.
Zotero 插件